Key result
Idarucizumab effectively and safely reverses dabigatran in patients experiencing major bleeding events.
Why the study?
Despite widespread use of non-vitamin K antagonist oral anticoagulants, a strong need for antidotes and reversal agents remains among physicians treating dabigatran patients.
This review summarizes the evidence and current recommendations for using idarucizumab to reverse dabigatran in patients with major bleeding.
Supports idarucizumab for dabigatran reversal in major bleeding; extends evidence synthesis but leaves open needs for prospective validation.
Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. Despite that, a strong need for antidotes/reversal agents is still reported by several physicians. Idarucizumab is a humanized monoclonal antibody fragment that binds specifically to dabigatran. Idarucizumab was approved in 2015 by the US Food and Drugs Administration and European Medicines Agency for reversal of anticoagulation activity in dabigatrantreated patients. This review briefly summarizes the experimental evidence about effectiveness and safety of idarucizumab. Furthermore, we review the current recommendations and experts' point of view about the use of antidotes/reversal agents in patients reporting a major bleeding event.
No takes yet. Share an insight, caveat, or question.
Proietti et al. (2018) conducted a review in Dabigatran anticoagulation reversal. Idarucizumab was evaluated. Idarucizumab is reviewed for its effectiveness and safety as a reversal agent for dabigatran-treated patients experiencing major bleeding events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: